Dimitri Azar - Novartis Non-Executive Independent Director

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

  Director
Dr. Dimitri Azar, M.D., was NonExecutive Independent Director of Novartis Inc. since February 2012. He is Member of the Governance, Nomination and Corporationrationrate Responsibilities Committee and the Research Development Committee. Dr. Azar is senior director of ophthalmological innovation at Verily Life Sciences. He has also served as dean of the University of Illinois at Chicago College of Medicine in the United States since 2011, and as professor of ophthalmology, bioengineering and pharmacology at UIC since 2006. From 2006 to 2011, he was head of the Department of Ophthalmology and Visual Sciences at UIC. He is a member of the American Ophthalmological Society, former president of the Chicago Ophthalmological Society, and presidentelect of the Chicago Medical Society. Additionally, he is on the board of the Tear Film and Ocular Surface Society, the board of Verb Surgical Inc., and the scientific board of Verily all based in the United States. Dr. Azar began his career at the American University of Beirut Medical Center in Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. His research on matrix metalloproteinases in corneal wound healing and angiogenesis was funded by the US National Institutes of Health since 1993. Dr. Azar practiced at the Wilmer Eye Institute at the Johns Hopkins Hospital School of Medicine in the US, and then returned to the Massachusetts Eye and Ear Infirmary as director of cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003
Age: 59  Director Since 2012  MBA    
41 61 324 1111  http://www.novartis.com
Azar holds a master?s degree from Harvard and an Executive MBA from the University of Chicago Booth School of Business.

Novartis Management Efficiency

Novartis AG has Return on Asset of 5.93 % which means that on every $100 spent on asset it made $5.93 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.16 %, implying that it generated $15.16 on every 100 dollars invested. Novartis management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Novartis Return on Average Equity is relatively stable at the moment as compared to the past year. Novartis reported last year Return on Average Equity of 0.17. As of 07/09/2020, Return on Invested Capital is likely to grow to 0.26, while Return on Average Assets are likely to drop 0.08. Novartis Average Assets are relatively stable at the moment as compared to the past year. Novartis reported last year Average Assets of 131.97 Billion. As of 07/09/2020, Tangible Asset Value is likely to grow to about 71.6 B, while Return on Average Assets are likely to drop 0.08. As of 07/09/2020, Total Liabilities is likely to grow to about 64.8 B. Also, Current Liabilities is likely to grow to about 29.2 B
The company has 36.69 B in debt with debt to equity (D/E) ratio of 0.72, which is OK given its current industry classification. Novartis AG has a current ratio of 0.73, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Ann CairnsAstrazeneca PLC
2014
Patricia RussoMerck Company
1995
Genevieve BergerAstrazeneca PLC
2012
Thomas GlanzmannGrifols S A
2017
Theodore SamuelsBristol Myers Squibb
2017
Jesse GoodmanGlaxoSmithKline PLC
2017
Shriti VaderaAstrazeneca PLC
2011
Michael EskewEli Lilly And
2008
Raul AlvarezEli Lilly And
2009
Antonio ParesGrifols S A
2014
Inigo MardonesGrifols S A
2017
Tim JacksonSmithAstrazeneca PLC
2015
Karen VousdenBristol Myers Squibb
2018
Jackson TaiEli Lilly And
2013
Stephen WrightGW Pharmaceuticals Plc
2005
Richard WhitleyGilead Sciences
2008
Jennifer DoudnaJohnson Johnson
2018
Vivienne CoxGlaxoSmithKline PLC
2017
Anne MulcahyJohnson Johnson
2012
Robert KidderMerck Company
2005
Manvinder BangaGlaxoSmithKline PLC
2016

Company Summary

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 109000 people.Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in Lichtstrasse 35 and employs 109,000 people. Novartis AG was previously known as NOVARTIS AG and was traded on BATS Exchange under the symbol NVSEF. Novartis is listed under Pharmaceutical Products category by Fama And French industry classification.

Novartis AG Leadership Team

Ton Buechner, Non-Executive Independent Director
Verena Briner, Non-Executive Independent Member of the Board
Chris Ilsley, President CEO
Steven Baert, Chief People & Organization Officer, Member of the Executive Committee
Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee
Richard Francis, Member of the Executive Committee and Division Head, Sandoz
Daniel Vasella, Honorary Chairman of the Board
Pierre Landolt, Member of the Board of Directors
Elizabeth Doherty, Non-Executive Independent Director
Erwin Vanhaecke, Head Novartis Group Quality
Elizabeth Barrett, CEO, Novartis Oncology
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Samir Shah, Global Head Investor Relations
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals
Srikant Datar, Non-Executive Independent Director
MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee
Simon Moroney, Director
Francesco Balestrieri, Chief Executive Officer of Sandoz, Member of the Executive Committee
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee
Joerg Reinhardt, Independent Non-Executive Chairman of the Board
Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC
Andrews C, Non-Executive Independent Director
Michele Galen, Head Communications
Charles Sawyers, Non-Executive Independent Member of the Board
John Tsai, Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee
Dimitri Azar, Non-Executive Independent Director
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Susanne Schaffert, CEO Novartis Oncology, Member of the Executive Committee
Enrico Vanni, Independent Non-Executive Vice Chairman of the Board
Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee
Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Alex Krauer, Honorary Chairman of the Board
Michael Ball, CEO of Alcon, Member of the Executive Committee
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz
Patrice Bula, Non-Executive Independent Director
Peter Kornicker, Chief Compliance Officer
Andreas Planta, Non-Executive Independent Director
Joseph Jimenez, CEO, Member of the Executive Committee
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director
William Winters, Non-Executive Independent Member of the Board
Ann Fudge, Non-Executive Independent Director
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel, Head of Corporate Strategy and External Affairs
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag
Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics
Bridgette Heller, Director

Stock Performance Indicators

Current Sentiment - NVS

Novartis AG Investor Sentiment

Predominant part of Macroaxis users are now bullish on Novartis AG. What is your trading attitude regarding investing in Novartis AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page